Malvern Instruments Acquires NanoSight - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Malvern Instruments Acquires NanoSight



Malvern Instruments, a provider of instrumentation for materials and biophysical characterization, has acquired nanoparticle characterization company NanoSight. The acquisition was completed on Sept. 27, 2013.
 
NanoSight has developed and commercialized Nanoparticle Tracking Analysis (NTA). The company’s instrumentation and software enable multi-parameter analysis and characterization of many different types of nanoscale particles. Nanosight’s ability to analyze particle size, concentration, zeta potential, and aggregation, closely aligns with Malvern’s Zetasizer range, extending Malvern’s solutions for those working at the nanoscale. 
 
NanoSight will continue to operate from its current facilities in Amesbury, Wiltshire, UK, under the existing management team.

Source: NanoSight

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here